Adoptive cell therapy uses cancer reactive T-cells to effectively treat cancer patients. Producing many persistent T-cells is critical for successful treatments. Researchers at the NCI seek licensing and/or co-development research collaborations for a novel method of producing effective T-cell populations using Akt inhibitors.
Researchers at the NCI have developed a novel treatment for adrenocortical cancer (ACC) by repositioning the drug niclosamide. New treatments for ACC can help patients with this rare and aggressive disease, where the current standard of care involves highly toxic options. The NCI seeks parties to license this method of treating adrenocortical cancer using niclosamide.
Recent research has demonstrated that neoantigen-specific T-cell receptors (TCRs) can be isolated from a cancer patient’s lymphocytes. These TCRs may be used to engineer populations of tumor-reactive T cells for cancer immunotherapies. Obtaining sequences of these functional TCRs is a critical initial step in preparing this type of personalized cancer treatment; however, current methods are time-consuming and labor-intensive. Scientists at the National Cancer Institute (NCI) have developed a rapid and robust method of isolating the sequences of mutation-specific TCRs to alleviate these issues; they seek licensing and/or co-development research collaborations for the development of a method for isolating the sequences of tumor-reactive TCRs. For collaboration opportunities, please contact Steven A. Rosenberg, M.D., Ph.D. at email@example.com.